key: cord-0818855-d7zkhf4m
authors: Patterson, Edward I.; Prince, Tessa; Anderson, Enyia R.; Casas-Sanchez, Aitor; Smith, Shirley L.; Cansado-Utrilla, Cintia; Turtle, Lance; Hughes, Grant L.
title: Methods of inactivation of SARS-CoV-2 for downstream biological assays
date: 2020-05-23
journal: bioRxiv
DOI: 10.1101/2020.05.21.108035
sha: 40dc3da27eb118aee19196c6ea6808aba5b8b0c3
doc_id: 818855
cord_uid: d7zkhf4m

The scientific community has responded to the COVID-19 pandemic by rapidly undertaking research to find effective strategies to reduce the burden of this disease. Encouragingly, researchers from a diverse array of fields are collectively working towards this goal. Research with infectious SARS-CoV-2 is undertaken in high containment laboratories, however, it is often desirable to work with samples at lower containment levels. To facilitate the transfer of infectious samples from high containment laboratories, we have tested methods commonly used to inactivate virus and prepare the sample for additional experiments. Incubation at 80°C, and a range of detergents and UV energies were successful at inactivating a high titre of SARS-CoV-2. These protocols can provide a framework for in house inactivation of SARS-CoV-2 in other laboratories, ensuring the safe use of samples in lower containment levels.

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 31 emerged in December 2019 in Wuhan, China, and spread to the rest of the world in a few 32 months causing a pandemic (1,2). This virus causes the coronavirus disease, known as 33 COVID-19, in humans and as of May 17, 2020, has infected almost 5,000,000 people and 34 caused over 300,000 deaths (3). Research on SARS-CoV-2 has increased exponentially since 35 the beginning of the pandemic and will likely continue growing until an effective vaccine is 36 developed. In the UK, and many other countries, SARS-CoV-2 is classified as a hazard group Several methods of inactivation are available, but since this is a novel virus, the effectiveness 43 of many of these methods on SARS-CoV-2 has not been tested yet. Some inactivation 44 approaches have been tested on SARS-CoV, a coronavirus which spread between November 45 2002 and September 2003 and whose genome presents a 80% shared identity with the new 46 SARS-CoV-2 (4). It is expected that the outcome of both physical and chemical inactivation 47 methods used against SARS-CoV-2 will be similar to SARS-CoV, but methods need to be 48 validated prior to use of the new virus isolate. 49 50 Several methods for virus inactivation are available and the choice of which approach is used 51 is often related to their compatibility with downstream applications. Heat inactivation has been 52 used for several viruses (5,6) and is a common method employed for antigen preservation of 53 viral and bacterial pathogens. To preserve proteins in the sample that are related to host 54 immune response, detergents and UV can be used to inactivate viruses (7,8). Detergents are 55 common additives in reagents used for virus inactivation, as well as RNA extraction from a 56 range of sample types. UV irradiation, which inactivates viruses by modifying their nucleic acid 57 structure, has been used successfully to inactivate many viruses, and in particular SARS-CoV 58 (9). Inactivation of SARS-CoV-2 through the use of UV would allow the safe use of the virus 59 within a CL2 laboratory and prevent the possibility of lab-acquired infections. Here we aim to 60 assess and describe physical and chemical inactivation protocols of SARS-CoV-2. Heat inactivation was performed by incubating 300 µl of SARS-CoV-2 stock at 80°C for 1 hour. 75

Inactivation with detergents (0.5% sodium dodecyl sulfate (SDS), 0.5% Triton X-100, 0.5% 76

Tween 20, 0.5% NP-40) were incubated with virus for 30 minutes at room temperature. UV 77 inactivation was performed using a CL1000 UVP Crosslinker (UVP, Upland, CA, USA). The 78 CL-1000 UVP Crosslinker consisted of 5 x 254 nm shortwave tubes, which is the 79 recommended wavelength for neutralising viruses, in particular SARS-CoV (9). Virus stock 80 was added (250 µl) into wells of a 24-well plate and placed without its lid on top of an ice block 81 inside the crosslinker. Plates were placed exactly 6 cm from the UV bulbs. Inactivation was performed at a range of UV energy exposures; 0.01 J/cm 2 -0.8 J/cm 2 . All inactivation 83 procedures were performed in triplicate, with the exception of NP-40 which was performed in 84 duplicate. 85 86

Heat treated samples were evaluated for viable virus in a TCID50 assay with Vero E6 cells, 88

using the entire volume of the sample. Control virus stocks containing 10 0 , 10 1 and 10 2 PFU 89 incubated at room temperature for 1 hour were used to determine the limit of detection of the 90 assay. TCID50 plates were passaged onto fresh cells for 4 days at least twice to ensure no 91 replicative virus remained. Cells were monitored daily for cytopathic effect (CPE). concentrated until £300 µl of sample remained. Sample was extracted and virus culture 97 medium was added to a final volume of 300 µl. Viable virus was evaluated in a TCID50 assay 98 as outlined above. Control virus stocks containing 10 0 , 10 1 and 10 2 PFU were diluted in PBS 99 and followed the above protocol with centrifugal filters to determine the limit of detection of the 100 assay. 101 102 Plaque assays and TCID50 assays were performed on untreated virus stocks and on UV 103 inactivated stocks in parallel. TCID50 plates were passaged onto fresh cells for 3 days at least 104 twice to ensure no replicative virus remained. TCID50 results were calculated using the 105 Spearman and Karber method as previously described (10). 106

We first determined the limits of sensitivity for our detection method by quantifying SARS-109

CoV-2 at 10 0 , 10 1 , or 10 2 PFU using TCID50 assays. This was done by quantifying viral titres 110 directly, or by passing the sample through a centrifugal column, which is used to remove the 111 inactivation agent before assaying on cells. Virus prepared without the centrifugal column was 112 detected down to dilutions of 10 0 PFU of SARS-CoV-2 ( Figure 1A) . The limit of detection with 113 the centrifugal columns was determined to be 10 1 PFU of SARS-CoV-2 ( Figure 1A) . evaluate their ability to inactivate SARS-CoV-2, including a range of common detergents and 151 determining the threshold of inactivation by UV exposure. The assay to assess infectious 152 particles was also shown to be sensitive, in some cases down to a single infectious virus 153 particle, and down 10 infectious particles/mL where a centrifugal column is used to 154 concentrate the sample. 

A new coronavirus 223 associated with human respiratory disease in China

A pneumonia 225 outbreak associated with a new coronavirus of probable bat origin

World Health Organization. Coronavirus (COVID-19)

Genomic characterisation and 230 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor 231 binding

Evaluation of the inactivation 233 of Venezuelan equine encephalitis virus by several common methods

Thermal stability and inactivation of 236 hepatitis C virus grown in cell culture

Virus 238 inactivation and protein recovery in a novel ultraviolet-C reactor

SARS-coronavirus 241 (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin 242 preparation

Inactivation of the coronavirus 244 that induces severe acute respiratory syndrome, SARS-CoV

Virus isolation and quantitation

Distribution and repair of bipyrimidine 250 photoproducts in solar UV-irradiated mammalian cells. Possible role of dewar 251 photoproducts in solar mutagenesis

Stability and 253 inactivation of SARS coronavirus

Heat inactivation of serum interferes with 255 the immunoanalysis of antibodies to SARS-CoV-2. medRxiv

Evaluation of heating 257 and chemical protocols for inactivating SARS-CoV-2. bioRxiv

Potential false-negative nucleic 259 acid testing results for Severe Acute Respiratory Syndrome Coronavirus 2 from 260 thermal inactivation of samples with low viral loads

Direct and indirect effects of UV radiation on DNA and 262 its components

Inactivation of SARS coronavirus by means of 264 povidone-iodine, physical conditions and chemical reagents

Analytical 267 validation of a COVID-19 qRT-PCR detection assay using a 384-well format and three 268 extraction methods

CoV-2) diagnosis by RT-PCR to increase capacity for national testing 271 programmes during a pandemic

Methods for successful 275 inactivation of Rift Valley fever virus in infected mosquitoes